<DOC>
	<DOCNO>NCT02038621</DOCNO>
	<brief_summary>To confirm efficacy safety XELOX capecitabine maintenance treatment advance gastric cancer ( AGC )</brief_summary>
	<brief_title>The Maintenance Therapy Capecitabine Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age ≥ 18 year old male female Patients stage IV gastric cancer pathology cytology image diagnosis , previous surgery radiotherapy chemotherapy patient stage IV gastric cancer progression , RECIST criterion evaluable lesion ; ECOG performance status score 02 ; Expected survival time three month ; Adequate hematologic parameter liver kidney function ; Bone marrow : absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L , platelets ≥ 75 × 109 / L , hemoglobin ≥ 80g / L ; Liver : bilirubin ≤ 1.5 time upper limit normal , ALT AST value ≤ 2.5 time upper limit normal ; Renal : serum creatinine ≤ ULN ; Informed consent patient agent , sign informed consent . For patient allergic capecitabine ; Patients CNS metastases Undermine integrity upper gastrointestinal tract , malabsorption syndrome , unable take oral medication ; Patients coronary heart disease , angina , myocardial infarction , arrhythmia , cerebral thrombosis , stroke serious cardiovascular cerebrovascular disease ; Or combination antitumor therapy patient participate clinical trial intervention ; Pregnancy breastfeed patient , fertility without take adequate contraceptive measure ; The researcher believe test suitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>